Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Sottini, Alessandra ^a   Capra, Ruggero ^a   Zanotti, Cinzia ^a   Chiarini, Marco ^a   Serana, Federico ^a,b   Ricotta, Doris ^b   Caimi, Luigi ^b   Imberti, Luisa ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; IMMUNOGLOBULIN; NATALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASSAY; B LYMPHOCYTE; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE; HUMAN; IMMUNOGLOBULIN PRODUCTION; K DELETING RECOMBINATION EXCISION CIRCLE ASSAY; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REAL TIME POLYMERASE CHAIN REACTION; SPECTRATYPING; T CELL RECEPTOR EXCISION CIRCLE ASSAY; T LYMPHOCYTE; V PRE B LYMPHOCYTE GENE 1; CASE CONTROL STUDY; CASE REPORT; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84859316003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034493     Document Type: Article

References (49)

1. Koralnik IJ, (2006) Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 60: 162-173.
2. Tan CS, Koralnik IJ, (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9: 425-437.
3. Major EO, (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61: 35-47.
4. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, et al. (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 65: 1596-1603.
5. del Pilar Martin M, Cravens PD, Winger R, Kieseier BC, Cepok S, et al. (2009) Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 66: 1016-1020.
6. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, et al. (2008) Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One 3: e2028.
7. Boster A, Hreha S, Berger JR, Bao F, Penmesta R, et al. (2009) Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 66: 593-599.
8. Berger JR, (2006) Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: 48-53.
9. Sabath B, Major E, (2002) Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 186: S180-S186.
10. Koralnik IJ, (2002) Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 8: 59-65.
11. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, et al. (2002) Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168: 499-504.
12. Berger JR, (2003) JCV-specific CD4 T cell response: another piece of the puzzle in explaining some aspects of AIDS associated PML. AIDS 17: 1557-1559.
13. Kalams SA, Walker BD, (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188: 2199-2204.
14. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, et al. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438-446.
15. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, et al. (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10: 745-758.
16. Rice GP, Hartung HP, Calabresi PA, (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336-1342.
17. Coisne C, Mao W, Engelhardt B, (2009) Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 182: 5909-5913.
18. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, et al. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59: 743-747.
19. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E, (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71: 1350-1354.
20. Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, et al. (2011) CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 17: 151-156.
21. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, et al. (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361: 1067-1074.
22. Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, et al. (2010) Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9: 264-272.
23. Sottini A, Ghidini C, Zanotti C, Chiarini M, Caimi L, et al. (2010) Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clin Immunol 136: 217-227.
24. Akatsuka Y, Martin EG, Madonik A, Barsoukov AA, Hansen JA, (1999) Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 53: 122-134.
25. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, et al. (2005) Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201: 805-816.
26. Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, et al. (1998) Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 4: 215-221.
27. Sarzotti-Kelsoe M, Win CM, Parrott RE, Cooney M, Moser BK, et al. (2009) Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood 114: 1445-1453.
28. Serana F, Sottini A, Chiarini M, Zanotti C, Ghidini C, et al. (2010) The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol 185: 7713-7722.
29. Gran B, Gestri D, Sottini A, Quiròs Roldàn E, Bettinardi A, et al. (1998) Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis. J Neuroimmunol 85: 22-32.
30. Sandrock A, Hotermans C, Richman S, Natarajan A, Lee S, et al. (2011) Risk stratification for Progressive Multifocal Leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. 63rd AAN Annual Meeting, April 9-16, Honolulu, HI. Abstract P03.248; retrieved from: http://www.abstracts2view.com/aan/.
31. Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, et al. (2010) Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68: 304-310.
32. Chesters PM, Heritage J, McCance DJ, (1983) Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 147: 676-684.
33. Yogo Y, Kitamura T, Sugimoto C, Ueki T, Aso Y, et al. (1990) Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 64: 3139-3143.
34. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO, et al. (1998) Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72: 9918-9923.
35. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K, (2008) Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 64: 379-387.
36. Naess H, Glad S, Storstein A, Rinaldo CH, Mørk SJ, et al. (2010) Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol 10: 32.
37. Serana F, Airò P, Chiarini M, Zanotti C, Scarsi M, et al. (2011) Thymic and bone marrow output in patients with common variable immunodeficiency. J Clin Immunol 31: 540-549.
38. Thewissen M, Linsen L, Somers V, Geusens P, Raus J, Stinissen P, (2005) Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients. Ann N Y Acad Sci 1051: 255-262.
39. Fox EJ, (2004) Mechanism of action of mitoxantrone. Neurology 63: S15-S18.
40. Geginat J, Lanzavecchia A, Sallusto F, (2003) Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101: 4260-4266.
41. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, et al. (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurol 71: 1261-1267.
42. Bauer SR, Huebner K, Budarf M, Finan J, Erikson J, et al. (1988) The human Vpre B gene is located on chromosome 22 near a cluster of V lambda gene segments. Immunogenetics 28: 328-333.
43. Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, et al. (2011) Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 68: 1428-1431.
44. Chapagain ML, Nerurkar VR, (2010) Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 202: 184-191.
45. Houff SA, Berger J, (2010) The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein-Barr virus-transformed B cells point to an important feature of JC virus biology? J Infect Dis 202: 181-183.
46. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, et al. (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318: 301-305.
47. Lindberg RL, Lindberg RL, Achtnichts L, Kuhle J, Kappos L, (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194: 153-164.
48. Berger JR, (2011) The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 24: 262-267.
49. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L, (2009) Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 5: e1000368.